title: [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
abstract: In the past six years, five new drugs have been approved by the FDA for the treatment of metastatic castrate-resistant prostate cancer. While the disease itself still remains incurable, the sequential use of these drugs can significantly prolong survival while maintaining good quality of life. Research from the past decade made it clear that androgen receptor-mediated processes play a central part in the progression of the disease. Hormonal mechanisms related to androgen-receptors can remain active until late stages of the disease. A deeper understanding of these mechanisms has led to the introduction of new endocrine therapies, which resulted in a change of the nomenclature. The identification and remodelling of androgen receptor mutations that are responsible for primary and secondary resistance developing during the new therapies can pave the way to new and more efficient androgen receptor inhibitor treatments. The aim of the review is to present the pathophysiology of the androgen receptor signaling axis at the receptor level, to review FDA-approved drugs and to draw attention to the most promising developments in the treatment of this disease. Orv. Hetil., 2017, 158(2), 42-49.
authors.affiliation: "C" Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet Budapest, Ráth György u. 7-9., 1122.
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Küronya
authors.affiliation: "C" Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet Budapest, Ráth György u. 7-9., 1122.
authors.forename: Krisztina
authors.initials: K
authors.lastname: Bíró
authors.affiliation: "C" Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet Budapest, Ráth György u. 7-9., 1122.
authors.forename: Fruzsina
authors.initials: F
authors.lastname: Gyergyay
authors.affiliation: "C" Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet Budapest, Ráth György u. 7-9., 1122.
authors.forename: Lajos
authors.initials: L
authors.lastname: Géczi
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents; D002369:Castration; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D011944:Receptors, Androgen / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014481:United States
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D011944:Receptors, Androgen
keywords: ARV7; abirateron; abiraterone; androgen receptor; androgénreceptor; castrate-resistant prostate cancer; enzalutamid; enzalutamide; galeteron; galeterone; kasztrációrezisztens prosztatadaganat